High Grade Neuroendocrine Cancer
2 clinical trials · Condition
◉ Watch High Grade Neuroendocrine Cancer
| Record | Firm | Date |
|---|---|---|
| Dose Determining Study of EXS74539 (REC-4539) in Participants With Select Solid Tumors (NCT07517198) | Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals, Inc. | 2026-04-13 |
| Study of Oral MRT-2359 in Selected Cancer Patients (NCT05546268) | Monte Rosa Therapeutics, Inc | 2022-10-12 |
Track High Grade Neuroendocrine Cancer automatically
Every clearance here is in the API, with alerts when new ones post.